Previous 10 | Next 10 |
Lixte Biotechnology Holdings (LIXT) +21%.LightPath Technologies (LPTH) +16%.Reata Pharmaceuticals (RETA) +14% as FDA requested pre-NDA meeting for Omaveloxolone.Verona Pharma (VRNA) +10%.Cerecor (CERC) +6%.TAT Technologies (TATT) +5% on partnership with Lufthansa Technik Shenzhen ...
Reata Pharmaceuticals (RETA) has received a communication from the FDA stating that, after a preliminary review of briefing materials for an upcoming Type C meeting, a pre-NDA meeting is the most appropriate format for a discussion of the development program for omaveloxolone in Friedreich...
PLANO, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it received a communication from the Division of Neurology ...
Cardinal Health’s valuation discount exists for a reason: BairdCardinal Health (CAH) is trading flat in the pre-market after Baird analyst Eric Coldwell downgraded the stock to neutral from outperform. The price target of $64.00 per share implies only ~10.0% upside to the last close.Wi...
Reata Pharmaceuticals, Inc. (RETA) Q1 2021 Earnings Conference Call May 6, 2021 08:30 ET Company Participants Warren Huff - Chief Executive Officer Colin Meyer - Chief Research and Development Officer Manmeet Soni - Chief Operating and Chief Financial Officer Dawn Bir - Chief Commercial Offic...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Q1 2021 Earnings Call May 6, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Reata Pharmaceuticals, Inc. (RETA) Q1 2021 Earnings Call Transcr...
Reata Pharmaceuticals (RETA): Q1 GAAP EPS of -$1.86 beats by $0.30.Revenue of $0.94M (-30.4% Y/Y) misses by $0.49M.Press Release For further details see: Reata Pharmaceuticals EPS beats by $0.30, misses on revenue
ANNOUNCES FDA ACCEPTED FOR FILING REATA’S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME IF APPROVED, BARDOXOLONE MAY BECOME THE FIRST APPROVED THERAPY FOR ALPORT SYNDROME, A LIFE-THREATENING DISEASE THAT AFFECTS 30,000 – ...
Reata Pharmaceuticals (NASDAQ:RETA) is scheduled to announce Q1 earnings results on Thursday, May 6th, before market open.The consensus EPS Estimate is -$1.73 (-94.4% Y/Y) and the consensus Revenue Estimate is $1.43M (+5.9% Y/Y).Over the last 2 years, RETA has beaten EPS estimates 38% of the ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...